Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A good CEO CFO Chairman would've reached out to Feuerstein long ago to try to win him over.
Rhoid is the ultimate ragger. It lacks conviction.
I get attacked here for pointing this out.
>>The paper claims a follow up phase 3 comparing dcvaxL to SoC has been in progress.
No. The data is seen as nebulous and that'd be why they're allegedly doing a confirmatory. Has to be a PFS trial using new techniques to monitor progression.
>>I don’t remember anything about such a trial and it would seem inappropriate to condemn trial participants to a placebo arm without benefit of dcvax.
You didn't even read what I said. You all just lash out without thinking.
Nothing will come out of further data collection. But if they're somehow running a stealth confirmatory, that'd be a new conversation here.
>>You’ve been here during these conversations. You should not be surprised.
Well, I always said they'd likely need to do a confirmatory trial for any regulator approval so this might be a game changer, if true. Although I don't know how that'd be possible without informing investors. But certainly enough time has gone by.
Is this a confirmatory trial that management failed to announce?
>> A follow up phase III clinical trial comparing DCVax-L to standard of care with placebo vaccines is ongoing.
...I told you UCLA would go into manufacturing biz for themselves, I told you they wouldn't hire more C suite, I told you there were no suitors, I told you NICE would lag...much that came true but because you all ignore me nothing ever credited.
And, that's your problem that you think most of them are wrong when actually most are right, but it's the timing that's difficult to catch right. Just recently for example, I told you all nothing would happen this summer. I told you all once the first insider pulled the trigger on sales we'd see more. I told you Les would continue to do more BBS when you all thought it was long over.
Still being a rhoid to skeptics even after all your ragging on this management. Makes sense. LOL
Advent is working on T and NK production too.
What kind of drivel is this? Almost sounds like another disciple veiled threat. This company's been shooting blanks for twenty five years.
Non tradable? The exercise on some of those options is 23 cents.
Maybe?? Isn't it sad management puts us all through wondering whether they're live or not.
Already told you that last BBS was prerecorded because the guy said the share price was 50 cents, so that means LG's is too.
I'm not seeing any steam. Reverse split / Restructure could be coming, IMO.
And we have no idea if that giftee still holds. Smart if they sold.
Or what? I get the sense there's no lead investor here. Some passive institutions but that's about all. I see they launched a lawsuit against management of AlloVir (Rightfully so, IMO) but it doesn't look to be going anywhere.
>> "they better not disappoint",
Or the giftees are selling here and this is the top??
What adds up is he's another Tuttle...I mean Duffy.
Come on! Does this sound like regulator approval to you?
Pg 544 & 545. "The results are considered encouraging."
https://www.oncotarget.com/article/28636/pdf/
Yet another event NWBO won't be attending.
BPGbio lead candidate, BPM31510, in patients with newly diagnosed glioblastoma multiforme (GBM) at the European Society for Medical Oncology (ESMO) Congress 2024, taking place September 13-17 in Barcelona.
https://finance.yahoo.com/news/bpgbio-presents-phase-2b-bpm31510-110000731.html
I see a lot of excitement driven postings this morning but can't figure out why??
Ignored
...I had hoped AlloVir might takeover Marker but so far nothing. Rather than buy Markers IP they're just burning through their cash. Now down to around $140M. Doesn't say a lot for Marker, IMO.
>>Such a wide-ranging failure of a company’s lead asset always has serious financial implications, and AlloVir said it will now “review strategic alternatives,” including a merger, company sale or divesting assets. The biotech ended September with $213.3 million on hand, it said.
...And, you know what happened next with AlloVir. Sick stuff! Any management attached to that story deserves skepticism.
>>In its third-quarter earnings report in November, the company promised a “catalyst-rich next 12 months” as the company prepared for “a potential 2025 launch” of posoleucel.
https://www.fiercebiotech.com/biotech/allovirs-shares-plunge-64-company-assess-options-wake-triple-phase-3-disaster
Nobody wants to see Vera and whoever else is left try to run more trials. Between AlloVir and Marker it's like a "Now you see it now you don't" magic show. Investors aren't even clear what happened as they watched their cash vanished! Hopefully this Pl result looks good and the IP gets bought quickly, and we're done.
Thank you.
So 2026 it is! LOL. Everyone good with that?
It's just Doc's sneaky way of extending the timelines on poor retail.
Why a dumb statement.
>>no one is talking about that because it is a moot point. What do you want Vera to do? Hope more people get cancer so enrollment won't have been a problem, as it seemingly is?
Nobody here is even talking about how much longer they remain on NASDAQ. An OTC move is inevitable unless Vera switches into high gear.
Someone out there besides me must see the insanity.
No. I gave up on that long ago. I consider it a major red flag when you see so many "Investors" unwilling to engage.
>>Are you still here pretending to want a constructive discussion about NWBO and the DCVax platform
Uh huh.
Are you really trying to make a case for averaging down with this one? Based on what some imaginary future share price?
In biotech.
LC, you’re an investor in NWBO?
PS- Are you doing anything different this time around in terms of the questions you ask management and getting straight answers?
I agree with much of what you say and that it should be fully enrolled by now. You're talking about 80 patients, right? My lowered expecting expects 30 but it really should be fully enrolled unless they're figuring out way to improve results as they move along.
Vera has practically no presence and that's extremely concerning.
>>No reason this shouldn't be fully enrolled right now.
LOL! Love it when you guys pull out the "Scientist" card like you boneheads somehow are running around in lab coats.
I'm an investor and presume most of you are too, although I have my doubts. The fact is that all these different therapies now coming online will eat into any profits that L might finally generate IF it ever gets off the ground. LL herself said no one therapy is going to work for GBM, you bunch of knuckleheads.
>> I understand you are trying to sound scientific. The sad fact is that if you had any respect for science, you would not be a minion today.